Key result
Novel lipid-lowering therapies target diverse pathways for atherosclerosis management in ongoing clinical development.
Answers are grounded in this paper and cite their sources.
Lipid-lowering is established as a proven intervention to reduce atherosclerosis and its complications. This article summarises imminent developments in lipid-lowering therapy, including new statins and cholesterol absorption inhibitors currently undergoing investigation for licensing. It also discusses other therapeutic targets such as squalene synthase, microsomal transfer protein (MTP), acyl-cholesterol acyl transferase (ACAT), cholesterol ester transfer protein (CETP), peroxosimal proliferator activating receptors (PPARs) and lipoprotein (a) (LP(a)), for which compounds have been developed and have at least reached trials in animal models. Lipid-lowering drugs are likely to prove a fast-developing area for novel treatments, as possible synergies exist between new and established compounds for the treatment of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Anthony S. Wierzbicki (2003) conducted a review in Atherosclerosis. Novel lipid-lowering agents (statins, cholesterol absorption inhibitors, and drugs targeting squalene synthase, MTP, ACAT, CETP, PPARs, and LP(a)) was evaluated. Novel lipid-lowering agents targeting cholesterol absorption, squalene synthase, MTP, ACAT, CETP, PPARs, and LP(a) are under development for atherosclerosis, with no quantitative outcomes reported.
Synapse has enriched 10 related papers. Consider them for comparative context: